search
Back to results

Implementation of a Comprehensive Intervention on Hypertension(HTN) and Type 2 Diabetes Mellitus(DM) at PHC Level

Primary Purpose

Hypertension, Diabetes Mellitus, Type 2

Status
Enrolling by invitation
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Implementation strategies
Sponsored by
National Center for Chronic and Noncommunicable Disease Control and Prevention, China CDC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Hypertension

Eligibility Criteria

35 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

For the quantitative questionnaire survey, the demander's population in phase 1 will include a total of 5464 patients with HTN and 7040 patients with type 2 DM in the 8 selected primary medical institutions.The demander's population in phase 2 is the same as that in phase 1.In phase 3, the demander's population will include a total of 2280 patients with HTN and 2656 patients with type 2 DM in the 8 selected primary medical institutions.

  • Inclusion criteria for respondents:①Patients with HTN and type 2 DM who have received basic public health service management for more than one year, and have no plan to move within the next year; ②Have normal communication ability and independent behavior ability; ③Volunteer to participate in the project questionnaire survey and provide the informed consents.
  • Exclusion criteria for respondents:①Patients with severe chronic diseases or in acute stage who cannot cooperate with investigators; ②Mental disorders or cognitive disorders (including dementia, cognitive impairment, deafness, etc.).

For the qualitative interview component, the provider's population will include policy-decision makers, managers, health professionals, healthcare workers who provide health management services for HTN and type 2 DM, and stakeholders who contain governmental officials/staff from civil society/non-governmental organization.Focus group discussions (FGDs) will be conducted. At each level, a group of people gets together for focus groups.During the interview, the specific number of interviewees shall be determined according to the principle of information saturation.

  • Inclusion criteria for interviewees:①Health care personnel responsible for community HTN or type 2 DM management; ②Responsible for the national basic public health service project -HTN, type 2 DM health management work for at least 12 months; ③Willing to participate in the project; ④Willing to be interviewed;⑤Good presentation and verbal communication skills.
  • Exclusion criteria for interviewees:①Health care workers who were not responsible for hypertensive or diabetic management;②Health care workers who carried out the management for less than 12 months;③Those who are not willing to participate in the project;④Unwilling to be interviewed;⑤Lack of expressive ability or difficulty in communicating in Mandarin; The demander's population will include a total of 80 patients with HTN and type 2 DM in the selected 8 primary medical institutions. The qualitative interview mainly adopts the personal in-depth interview method to understand the main problems in the implementation of the intervention measures, explore the causes of the problems, and possible improvement measures and suggestions.
  • Inclusion criteria include:①patients who have participated in management;②patients who are active in conversation;③patients who are willing to participate in interviews.
  • Exclusion criteria for patients:①patients with hypertension or diabetes who do not participate in the management;②patients who are not willing to be interviewed.

Sites / Locations

  • National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention groups

Control groups

Arm Description

as same as before

Outcomes

Primary Outcome Measures

Awareness change:Change from Baseline Awareness at 3, 6,9 months
Awareness of HTN/ type 2 DM in population:% awareness towards HTN/ type 2 DM in population.Survey method will be used to assess this outcome measure.
Screening rate change:Change from Baseline Screening rate at 3, 6,9 months
Screening rate of patients with HTN/ type 2 DM:% patients with HTN/ type 2 DM screened among those who have ever screened blood pressure/blood sugar.Data will be obtained from administrative record.
Diagnostic rate change:Change from Baseline Diagnostic rate at 3, 6,9 months
Diagnostic rate of patients with HTN/ type 2 DM:% patients with HTN/ type 2 DM diagnosed among those who have been screened blood pressure/blood sugar.Data will be obtained from administrative record.
Treatment rate change:Change from Baseline Treatment rate at 3, 6,9 months
Treatment rate of patients with HTN:% patients with HTN who took antihypertensive drugs in the last two weeks was determined among those who have been diagnosed blood pressure; Treatment rate of patients with type 2 DM:% patients with type 2 DM who have taken treatment measures (including lifestyle intervention and/or medication) among those who have been diagnosed blood sugar.Data will be obtained from administrative record.
Control rate change:Change from Baseline Control rate at 3, 6,9 months
Control rate of patients with HTN/type 2 DM:% patients whose blood pressure/ blood sugar are controlled among those who have been treated.Data will be obtained from administrative record.
Implementation strategies use change: Change from Baseline Implementation at 3, 6,9 months
Implementation strategies use:qualitative interviews with managers of health centers.Interviews method will be used to assess this outcome measure.
Supervision change: Change from Baseline Implementation at 3, 6,9 months
Supervision model: % scheduled supervision field visits completed.Data will be obtained from administrative data.
Referral completeness change: Change from Baseline Implementation at 3, 6,9 months
Referral completeness: % referrals completed as prescribed by the clinical algorithm.Data will be obtained from administrative data.
Adaptations to protocol change: Change from Baseline Implementation at 3, 6,9 months
Adaptations to protocol during intervention period: qualitative interviews with managers of local health department and health centers.Interviews method will be used to assess this outcome measure.
Implementation change: Change from Baseline Implementation at 3, 6,9 months
Qualitative assessment: qualitative interviews with managers of health.Interviews method will be used to assess this outcome measure.

Secondary Outcome Measures

Coverage change: Change from Baseline Reach at 3, 6,9 months
Coverage of population receiving health service for HTN and type 2 DM:proportion of target population receiving HTN and DM service.Data will be obtained from administrative data.
Screening coverage of eligible for HTN change: Change from Baseline Reach at 3, 6,9 months
Screening coverage of eligible for HTN:proportion of eligible for HTN receiving screening.Data will be obtained from administrative data.
Screening coverage of eligible for type 2 DM change: Change from Baseline Reach at 3, 6,9 months
Screening coverage of eligible for type 2 DM:proportion of eligible for type 2 DM receiving screening.Data will be obtained from administrative data.
Coverage of screening for patients with HTN/type 2 DM change: Change from Baseline Reach at 3, 6,9 months
Coverage of screening for patients with HTN/type 2 DM:% patients with HTN/type 2 DM who have been screened for hypertension/ diabetes.Data will be obtained from administrative data.
Readiness change: Change from Baseline Adoption at 3, 6,9 months
Readiness for implementation:a checklist to check readiness for implementation using.Data will be obtained from administrative data.
Health centers/clinic's adoption change: Change from Baseline Adoption at 3, 6,9 months
Health centers/clinic's adoption: % proportion of health centers/clinics implemented lifestyle intervention and/or medication.Data will be obtained from administrative data.
PHC professional's adoption change: Change from Baseline Adoption at 3, 6, 9 months
PHC professional's adoption:% of PHC professionals trained in implementing the guidelines for HTN and DM.Data will be obtained from administrative data.
Timely adoption
Timely adoption:# early adopters at the local site. Observation methods will be used to assess this outcome measure.
Leader adoption change: Change from Baseline Adoption at 3, 6,9 months
Leader adoption: # leaders recruited/designated/trained for the change effort in intervention implementation.Interview and observation methods will be used to assess this outcome measure.
Institution adoption change: Change from Baseline Adoption at 3, 6,9 months
Institution adoption:% intended Institution incorporated Administrative of HTN and DM in their routine service systems.Interview and observation methods will be used to assess this outcome measure.
Follow-up fidelity change: Change from Baseline Fidelity at at 3, 6,9 months
Follow-up fidelity: % patients with "adequate" number of follow-up visits received.Data will be obtained from administrative data(records).
Health professionals implemented guidelines/protocol change: Change from Baseline Fidelity at at 3, 6,9 months
Health professionals implemented guidelines /protocol: % of PHC professionals implemented according to the guidelines/protocol in actual work. Interview and observation methods will be used to assess this outcome measure.
Qualitative assessment-Behavior changes sustained (staff)
Long-term maintenance of changes in management behavior related to hypertension/type 2 DM. Interview and observation methods will be used to assess this outcome measure.
HTN and type 2 DM institutionalized
HTN and type 2 DM become institutionalized or part of the routine organizational practices.Data will be obtained from administrative data and survey.
Settings continue the intervention
proportion and representativeness of settings that continue the intervention.Data will be obtained from administrative data.
Total intervention cost
Total intervention cost per patient.Data will be obtained from administrative data.
Total treatment cost
Total treatment cost per patient.Data will be obtained from administrative data.
Intervention maintenance costs
% breakdown of maintenance (recurring) costs (ongoing training, personnel, materials, and other).Data will be obtained from administrative data.
Facility vs. community costs
% of costs of healthcare divided between facility level and community level.Data will be obtained from administrative data.
out-of-pocket patient costs
% out-of-pocket patient costs.Survey method will be used to assess this outcome measure.
Qualitative assessment-maintenance:
Interviews method will be used to assess this outcome measure.

Full Information

First Posted
February 28, 2022
Last Updated
April 27, 2022
Sponsor
National Center for Chronic and Noncommunicable Disease Control and Prevention, China CDC
Collaborators
World Health Organization
search

1. Study Identification

Unique Protocol Identification Number
NCT05353699
Brief Title
Implementation of a Comprehensive Intervention on Hypertension(HTN) and Type 2 Diabetes Mellitus(DM) at PHC Level
Official Title
Implementation of a Comprehensive Intervention on Hypertension(HTN) and Type 2 Diabetes Mellitus(DM) at PHC Level: a Hybrid Type II Cluster-controlled Multisite Effectiveness-implementation Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Enrolling by invitation
Study Start Date
May 1, 2022 (Anticipated)
Primary Completion Date
January 31, 2023 (Anticipated)
Study Completion Date
January 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Center for Chronic and Noncommunicable Disease Control and Prevention, China CDC
Collaborators
World Health Organization

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
Background: The disease burden of hypertension(HTN) and type 2 diabetes mellitus(DM) is rising rapidly in China.Comprehensive interventions(Implementation strategies for providers and interventions for patients) are critical to strengthen primary health care systems and address the burden of multiple comorbidities. In order to promote equal access to health services and narrow the gap in population health, China has launched the national Essential Public Health Services Equity Programme (EPHSEP) nationwide. EPHSEP contains guidelines for health management services for HTN and type 2 DM. The program has been in operation for 10 years. However, the management of HTN and type 2 DM in China is far from satisfactory. The purpose of this study is to understand current control and management situation of HTN and type 2 DM, investigate the barriers and facilitators in the implementation of HTN and type 2 DM service delivery standards, propose feasible implementation strategies,implement in certain areas,and to evaluate the effectiveness of interventions and the performance and impact of implementation strategies. Methods: Based on previous work,four community health service centres and four township health centres will be selected in West Coast District of Qingdao city of Shandong province,Suzhou City of Jiangsu province, Changsha city of Hunan province and Luohe city of Henan Province.In each of the four provinces,one community health service center and one township health center will be selected.Two community health service centres and two township health centres will be selected as the intervention groups, and the other community health service centres and township health centres will be selected as the control groups. The study will be divided into three phases: Phase 1, 2 and 3. Phase 1 and phase 2 cross-sectional studies are the basis for phase 3 intervention studies. Phase 1 will be conducted from March 2022 to April 2022.In phase 1, a quantitative questionnaire survey will be conducted among 5464 HTN and 7040 type 2 DM patients in 8 community health service centers to obtain the data of awareness rate, screening rate, diagnosis rate, treatment rate, control rate and management service of hypertension and type 2 diabetes patients,so as to understand current control and management situation of HTN and type 2 DM. Phase 2 will be conducted in April 2022. In phase 2, about 64 medical staff and related managers providing HTN and type 2 DM health management services and 80 patients with HTN and type 2 DM in 8 community health service centers will be investigated through qualitative interviews,so as to investigate the barriers and facilitators in the implementation of HTN and type 2 DM service delivery standards and to propose feasible implementation strategies. Phase 3 will be conducted a mixed-methods type 2 hybrid effectiveness-implementation study from May 2022 to January 2023. Interventions are divided into four levels through a cascading model of screening, diagnosis, treatment, and control. Implementation strategies are divided into 6 categories according to Implementation Mapping: Capacity-building strategies(Recruit, designate, and train for leadership; Work with educational institutions), Supervision(Provide clinical supervision), Integration strategies(Remind clinicians; Use data warehousing techniques), Implementation process Strategies(Identify and prepare champions; Identify early adopters; Inform local opinion leaders; Involve patients/consumers and family members; Obtain and use patients/consumers and family feedback), Dissemination strategies(Make training dynamic), Scale-up strategies(Use train-the-trainer strategies;Place innovation on fee for service lists/formularies). We will adopt between site design to select 4(2*2 )community health service centers and 4(2*2)township health centers, among which 2 community health service centers and 2 township health centers will implement the strategy, while the other selected sites will not implement the strategy. The 2*2 community health service centers and 2*2 township health centers will be divided into group matching control and self pre- and post-control. In phase 3, 2280 patients with HTN and 2656 patients with type 2 DM will be surveyed by quantitative questionnaire, and about 64 medical staff and related managers providing HTN and type 2 DM health management services will be surveyed by qualitative interview. This is to implement improved implementation strategies and to assess the effectiveness of interventions and the performance and impact of implementation strategies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
Participant
Allocation
Randomized
Enrollment
12648 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention groups
Arm Type
Experimental
Arm Title
Control groups
Arm Type
No Intervention
Arm Description
as same as before
Intervention Type
Other
Intervention Name(s)
Implementation strategies
Intervention Description
We will adopt implementation strategies,which include Capacity-building strategies, Supervision, Integration strategies, Implementation process strategies, Dissemination strategies, Scale-up strategies.Firstly,Capacity-building strategies include:recruit, designate, and train for leadership; work with educational institutions.Secondly,Supervision includes provide clinical supervision;Thirdly,Integration strategies include: remind clinicians; use data warehousing techniques.Fourthly,Implementation process strategies include: identify and prepare champions; identify early adopters; inform local opinion leaders; involve patients/consumers and family members; obtain and use patients/consumers and family feedback.Fifthly,Dissemination strategies include: make training dynamic.Finally,Scale-up strategies include: use train-the-trainer strategies;place innovation on fee for service lists/formularies.
Primary Outcome Measure Information:
Title
Awareness change:Change from Baseline Awareness at 3, 6,9 months
Description
Awareness of HTN/ type 2 DM in population:% awareness towards HTN/ type 2 DM in population.Survey method will be used to assess this outcome measure.
Time Frame
during the intervention; immediately after the intervention
Title
Screening rate change:Change from Baseline Screening rate at 3, 6,9 months
Description
Screening rate of patients with HTN/ type 2 DM:% patients with HTN/ type 2 DM screened among those who have ever screened blood pressure/blood sugar.Data will be obtained from administrative record.
Time Frame
during the intervention; immediately after the intervention
Title
Diagnostic rate change:Change from Baseline Diagnostic rate at 3, 6,9 months
Description
Diagnostic rate of patients with HTN/ type 2 DM:% patients with HTN/ type 2 DM diagnosed among those who have been screened blood pressure/blood sugar.Data will be obtained from administrative record.
Time Frame
during the intervention; immediately after the intervention
Title
Treatment rate change:Change from Baseline Treatment rate at 3, 6,9 months
Description
Treatment rate of patients with HTN:% patients with HTN who took antihypertensive drugs in the last two weeks was determined among those who have been diagnosed blood pressure; Treatment rate of patients with type 2 DM:% patients with type 2 DM who have taken treatment measures (including lifestyle intervention and/or medication) among those who have been diagnosed blood sugar.Data will be obtained from administrative record.
Time Frame
during the intervention; immediately after the intervention
Title
Control rate change:Change from Baseline Control rate at 3, 6,9 months
Description
Control rate of patients with HTN/type 2 DM:% patients whose blood pressure/ blood sugar are controlled among those who have been treated.Data will be obtained from administrative record.
Time Frame
during the intervention; immediately after the intervention
Title
Implementation strategies use change: Change from Baseline Implementation at 3, 6,9 months
Description
Implementation strategies use:qualitative interviews with managers of health centers.Interviews method will be used to assess this outcome measure.
Time Frame
during the intervention; immediately after the intervention
Title
Supervision change: Change from Baseline Implementation at 3, 6,9 months
Description
Supervision model: % scheduled supervision field visits completed.Data will be obtained from administrative data.
Time Frame
during the intervention; immediately after the intervention
Title
Referral completeness change: Change from Baseline Implementation at 3, 6,9 months
Description
Referral completeness: % referrals completed as prescribed by the clinical algorithm.Data will be obtained from administrative data.
Time Frame
during the intervention; immediately after the intervention
Title
Adaptations to protocol change: Change from Baseline Implementation at 3, 6,9 months
Description
Adaptations to protocol during intervention period: qualitative interviews with managers of local health department and health centers.Interviews method will be used to assess this outcome measure.
Time Frame
during the intervention; immediately after the intervention
Title
Implementation change: Change from Baseline Implementation at 3, 6,9 months
Description
Qualitative assessment: qualitative interviews with managers of health.Interviews method will be used to assess this outcome measure.
Time Frame
during the intervention; immediately after the intervention
Secondary Outcome Measure Information:
Title
Coverage change: Change from Baseline Reach at 3, 6,9 months
Description
Coverage of population receiving health service for HTN and type 2 DM:proportion of target population receiving HTN and DM service.Data will be obtained from administrative data.
Time Frame
during the intervention; immediately after the intervention
Title
Screening coverage of eligible for HTN change: Change from Baseline Reach at 3, 6,9 months
Description
Screening coverage of eligible for HTN:proportion of eligible for HTN receiving screening.Data will be obtained from administrative data.
Time Frame
during the intervention; immediately after the intervention
Title
Screening coverage of eligible for type 2 DM change: Change from Baseline Reach at 3, 6,9 months
Description
Screening coverage of eligible for type 2 DM:proportion of eligible for type 2 DM receiving screening.Data will be obtained from administrative data.
Time Frame
during the intervention; immediately after the intervention
Title
Coverage of screening for patients with HTN/type 2 DM change: Change from Baseline Reach at 3, 6,9 months
Description
Coverage of screening for patients with HTN/type 2 DM:% patients with HTN/type 2 DM who have been screened for hypertension/ diabetes.Data will be obtained from administrative data.
Time Frame
during the intervention; immediately after the intervention
Title
Readiness change: Change from Baseline Adoption at 3, 6,9 months
Description
Readiness for implementation:a checklist to check readiness for implementation using.Data will be obtained from administrative data.
Time Frame
during the intervention; immediately after the intervention
Title
Health centers/clinic's adoption change: Change from Baseline Adoption at 3, 6,9 months
Description
Health centers/clinic's adoption: % proportion of health centers/clinics implemented lifestyle intervention and/or medication.Data will be obtained from administrative data.
Time Frame
during the intervention; immediately after the intervention
Title
PHC professional's adoption change: Change from Baseline Adoption at 3, 6, 9 months
Description
PHC professional's adoption:% of PHC professionals trained in implementing the guidelines for HTN and DM.Data will be obtained from administrative data.
Time Frame
during the intervention; immediately after the intervention
Title
Timely adoption
Description
Timely adoption:# early adopters at the local site. Observation methods will be used to assess this outcome measure.
Time Frame
during the intervention
Title
Leader adoption change: Change from Baseline Adoption at 3, 6,9 months
Description
Leader adoption: # leaders recruited/designated/trained for the change effort in intervention implementation.Interview and observation methods will be used to assess this outcome measure.
Time Frame
during the intervention; immediately after the intervention
Title
Institution adoption change: Change from Baseline Adoption at 3, 6,9 months
Description
Institution adoption:% intended Institution incorporated Administrative of HTN and DM in their routine service systems.Interview and observation methods will be used to assess this outcome measure.
Time Frame
during the intervention; immediately after the intervention
Title
Follow-up fidelity change: Change from Baseline Fidelity at at 3, 6,9 months
Description
Follow-up fidelity: % patients with "adequate" number of follow-up visits received.Data will be obtained from administrative data(records).
Time Frame
during the intervention; immediately after the intervention
Title
Health professionals implemented guidelines/protocol change: Change from Baseline Fidelity at at 3, 6,9 months
Description
Health professionals implemented guidelines /protocol: % of PHC professionals implemented according to the guidelines/protocol in actual work. Interview and observation methods will be used to assess this outcome measure.
Time Frame
during the intervention; immediately after the intervention
Title
Qualitative assessment-Behavior changes sustained (staff)
Description
Long-term maintenance of changes in management behavior related to hypertension/type 2 DM. Interview and observation methods will be used to assess this outcome measure.
Time Frame
15 months
Title
HTN and type 2 DM institutionalized
Description
HTN and type 2 DM become institutionalized or part of the routine organizational practices.Data will be obtained from administrative data and survey.
Time Frame
immediately after the intervention
Title
Settings continue the intervention
Description
proportion and representativeness of settings that continue the intervention.Data will be obtained from administrative data.
Time Frame
immediately after the intervention
Title
Total intervention cost
Description
Total intervention cost per patient.Data will be obtained from administrative data.
Time Frame
immediately after the intervention
Title
Total treatment cost
Description
Total treatment cost per patient.Data will be obtained from administrative data.
Time Frame
immediately after the intervention
Title
Intervention maintenance costs
Description
% breakdown of maintenance (recurring) costs (ongoing training, personnel, materials, and other).Data will be obtained from administrative data.
Time Frame
immediately after the intervention
Title
Facility vs. community costs
Description
% of costs of healthcare divided between facility level and community level.Data will be obtained from administrative data.
Time Frame
immediately after the intervention
Title
out-of-pocket patient costs
Description
% out-of-pocket patient costs.Survey method will be used to assess this outcome measure.
Time Frame
immediately after the intervention
Title
Qualitative assessment-maintenance:
Description
Interviews method will be used to assess this outcome measure.
Time Frame
immediately after the intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
For the quantitative questionnaire survey, the demander's population in phase 1 will include a total of 5464 patients with HTN and 7040 patients with type 2 DM in the 8 selected primary medical institutions.The demander's population in phase 2 is the same as that in phase 1.In phase 3, the demander's population will include a total of 2280 patients with HTN and 2656 patients with type 2 DM in the 8 selected primary medical institutions. Inclusion criteria for respondents:①Patients with HTN and type 2 DM who have received basic public health service management for more than one year, and have no plan to move within the next year; ②Have normal communication ability and independent behavior ability; ③Volunteer to participate in the project questionnaire survey and provide the informed consents. Exclusion criteria for respondents:①Patients with severe chronic diseases or in acute stage who cannot cooperate with investigators; ②Mental disorders or cognitive disorders (including dementia, cognitive impairment, deafness, etc.). For the qualitative interview component, the provider's population will include policy-decision makers, managers, health professionals, healthcare workers who provide health management services for HTN and type 2 DM, and stakeholders who contain governmental officials/staff from civil society/non-governmental organization.Focus group discussions (FGDs) will be conducted. At each level, a group of people gets together for focus groups.During the interview, the specific number of interviewees shall be determined according to the principle of information saturation. Inclusion criteria for interviewees:①Health care personnel responsible for community HTN or type 2 DM management; ②Responsible for the national basic public health service project -HTN, type 2 DM health management work for at least 12 months; ③Willing to participate in the project; ④Willing to be interviewed;⑤Good presentation and verbal communication skills. Exclusion criteria for interviewees:①Health care workers who were not responsible for hypertensive or diabetic management;②Health care workers who carried out the management for less than 12 months;③Those who are not willing to participate in the project;④Unwilling to be interviewed;⑤Lack of expressive ability or difficulty in communicating in Mandarin; The demander's population will include a total of 80 patients with HTN and type 2 DM in the selected 8 primary medical institutions. The qualitative interview mainly adopts the personal in-depth interview method to understand the main problems in the implementation of the intervention measures, explore the causes of the problems, and possible improvement measures and suggestions. Inclusion criteria include:①patients who have participated in management;②patients who are active in conversation;③patients who are willing to participate in interviews. Exclusion criteria for patients:①patients with hypertension or diabetes who do not participate in the management;②patients who are not willing to be interviewed.
Facility Information:
Facility Name
National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100050
Country
China

12. IPD Sharing Statement

Learn more about this trial

Implementation of a Comprehensive Intervention on Hypertension(HTN) and Type 2 Diabetes Mellitus(DM) at PHC Level

We'll reach out to this number within 24 hrs